Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy

A previously hemostatically asymptomatic patient with common variable hypogammaglobulinemia was given everolimus to prevent growth of her liver. Within several months, the patient developed a severe bleeding disorder. The bleeding was due to fibrin polymerization defect that upon sequencing was show...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkulova, Alona A., Mitchell, Steven C., Merkulov, Sergei, Wolberg, Alisa S., Neerman-Arbez, Marguerite, Schmaier, Alvin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729062/
https://www.ncbi.nlm.nih.gov/pubmed/33330551
http://dx.doi.org/10.3389/fmed.2020.591546
_version_ 1783621378338979840
author Merkulova, Alona A.
Mitchell, Steven C.
Merkulov, Sergei
Wolberg, Alisa S.
Neerman-Arbez, Marguerite
Schmaier, Alvin H.
author_facet Merkulova, Alona A.
Mitchell, Steven C.
Merkulov, Sergei
Wolberg, Alisa S.
Neerman-Arbez, Marguerite
Schmaier, Alvin H.
author_sort Merkulova, Alona A.
collection PubMed
description A previously hemostatically asymptomatic patient with common variable hypogammaglobulinemia was given everolimus to prevent growth of her liver. Within several months, the patient developed a severe bleeding disorder. The bleeding was due to fibrin polymerization defect that upon sequencing was shown to be dysfibrinogenemia Krakow III. Elimination of the mTor inhibitor ameliorated the clinical bleeding state.
format Online
Article
Text
id pubmed-7729062
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77290622020-12-15 Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy Merkulova, Alona A. Mitchell, Steven C. Merkulov, Sergei Wolberg, Alisa S. Neerman-Arbez, Marguerite Schmaier, Alvin H. Front Med (Lausanne) Medicine A previously hemostatically asymptomatic patient with common variable hypogammaglobulinemia was given everolimus to prevent growth of her liver. Within several months, the patient developed a severe bleeding disorder. The bleeding was due to fibrin polymerization defect that upon sequencing was shown to be dysfibrinogenemia Krakow III. Elimination of the mTor inhibitor ameliorated the clinical bleeding state. Frontiers Media S.A. 2020-11-27 /pmc/articles/PMC7729062/ /pubmed/33330551 http://dx.doi.org/10.3389/fmed.2020.591546 Text en Copyright © 2020 Merkulova, Mitchell, Merkulov, Wolberg, Neerman-Arbez and Schmaier. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Merkulova, Alona A.
Mitchell, Steven C.
Merkulov, Sergei
Wolberg, Alisa S.
Neerman-Arbez, Marguerite
Schmaier, Alvin H.
Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title_full Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title_fullStr Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title_full_unstemmed Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title_short Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy
title_sort case report: unmasked inherited dysfibrinogenemia after everolimus therapy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729062/
https://www.ncbi.nlm.nih.gov/pubmed/33330551
http://dx.doi.org/10.3389/fmed.2020.591546
work_keys_str_mv AT merkulovaalonaa casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy
AT mitchellstevenc casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy
AT merkulovsergei casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy
AT wolbergalisas casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy
AT neermanarbezmarguerite casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy
AT schmaieralvinh casereportunmaskedinheriteddysfibrinogenemiaaftereverolimustherapy

Ejemplares similares